BC Innovations | Feb 15, 2017
Distillery Therapeutics

Infectious disease

INDICATION: Candida Mouse studies suggest inhibiting JNK1 could help treat Candida albicans infection. In a mouse model of C. albicans infection, knockout of JNK1 or two JNK1 inhibitor tool compounds decreased fungal burden and inflammation...
BC Innovations | Nov 15, 2016
Distillery Therapeutics

Infectious disease

INDICATION: Encephalitis Cell culture and mouse studies suggest inhibiting JNK1 or its substrate AP-1 could help treat the viral infection Japanese encephalitis (JE). In JE virus-infected human glioma and murine microglial cell lines, a JNK...
BC Innovations | Aug 18, 2011
Distillery Therapeutics

Indication: Various

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Various Diabetes; liver failure c-Jun N-terminal kinase (JNK) In vitro and mouse studies suggest compounds blocking both the ATP- and substrate-binding sites...
BC Innovations | Apr 28, 2011
Distillery Therapeutics

Indication: Cardiovascular disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Marfan syndrome MAP kinase 3 (MAPK3; ERK-1); MAPK1 (ERK-2); MAP kinase kinase 1 (MAP2K1; MEK1); MAP2K2 (MEK2); c-jun N-terminal kinase...
BC Week In Review | Aug 16, 2010
Company News

PregLem, Merck KGaA deal

Merck's Merck Serono S.A. unit granted PregLem exclusive, worldwide rights to develop and commercialize bentamapimod . Merck will receive an upfront payment and is eligible for milestones and royalties. PregLem said it plans to begin a...
Items per page:
1 - 5 of 5